ASLAN PHARMACEUTICALS LIMITED

(ASLN)
  Report
Delayed Nasdaq  -  03:59 2022-06-24 pm EDT
0.4872 USD   +5.84%
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/23Asian ADRs Move Higher in Thursday Trading
MT
06/22Asian ADRs Move Lower in Wednesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
0.387(c) 0.425(c) 0.4575(c) 0.4603(c) 0.4872(c) Last
275 184 97 901 525 354 736 105 123 325 Volume
-0.51% +9.82% +7.65% +0.61% +5.84% Change
More quotes
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 -1 691 M -56,9 M -56,9 M
Net Debt 2022 - - -
P/E ratio 2022 -0,60x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -2 982 M -100 M -100 M
Net Debt 2023 - - -
P/E ratio 2023 -0,34x
Yield 2023 -
Capitalization 1 010 M 34,0 M 34,0 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 27
Free-Float 41,1%
More Financials
Company
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a human monoclonal antibody that binds to the IL-13 receptor ╬▒1 subunit (IL-13R╬▒1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is... 
More about the company
All news about ASLAN PHARMACEUTICALS LIMITED
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/23Asian ADRs Move Higher in Thursday Trading
MT
06/22Asian ADRs Move Lower in Wednesday Trading
MT
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/17Asian ADRs Nudge Higher in Friday Trading
MT
06/16Asian ADRs Tumble in Thursday Trading
MT
06/15Asian ADRs Move Higher in Wednesday Trading
MT
06/14Asian ADRs Climb Higher in Tuesday Trading
MT
06/10Asian ADRs Move Sharply Lower in Friday Trading
MT
06/09Asian ADRs Move Lower in Thursday Trading
MT
06/08Asian ADRs Move Higher in Wednesday Trading
MT
06/08ASLAN PHARMACEUTICALS : Company Presentation June 2022
PU
06/07ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Ro..
GL
06/07ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Ro..
AQ
06/07ASLAN Pharmaceuticals Limited Initiates Scientific Collaboration to Investigate the Dis..
CI
More news
News in other languages on ASLAN PHARMACEUTICALS LIMITED
06/24Les ADR asiatiques grimpent dans la négociation de vendredi
06/23Les ADR asiatiques sont en hausse jeudi
06/22Les ADR asiatiques sont en baisse mercredi
06/21Les ADR européens en forte hausse dans les échanges de mardi
06/17Les ADR asiatiques en hausse dans les échanges de vendredi
More news
Analyst Recommendations on ASLAN PHARMACEUTICALS LIMITED
More recommendations
Chart ASLAN PHARMACEUTICALS LIMITED
Duration : Period :
ASLAN Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASLAN PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,49 $
Average target price 5,50 $
Spread / Average Target 1 029%
EPS Revisions
Managers and Directors
Carl Aslan Jason Morton Firth Chief Executive Officer & Director
Kiran Kumar Asarpota Chief Operating Officer & Head-Finance
Andrew James Howden Non-Executive Chairman
Alexandre Kaoukhov Chief Medical Officer
Robert E. Hoffman Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ASLAN PHARMACEUTICALS LIMITED-56.50%34
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574